Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 16/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 16/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 16/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.56 |
| ▸ | PTGIR | P43119 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786823 | 0.76 | CFB (0.54) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6789271 | 0.76 | ADRA2A (0.50) | NISCHADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL6791315 | 0.76 | CFB (0.61) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6788647 | 0.76 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL4672878 | 0.75 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12129516 | 0.74 | SYK (0.50) | — | |
| SCHEMBL1670195 | 0.73 | KMT2A (0.48) | NISCH | |
| SCHEMBL7033369 | 0.73 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL8791496 | 0.73 | FGFR2 (0.56) | — | |
| SCHEMBL11948704 | 0.73 | FGFR2 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198803-A1 | Such as 5-(methoxycarbonylamino)-N - acetyltryptamine; therapy for ocular hypertension; vision defects | PINTOR JESUS J (ES) | 2004-10-07 | — | — | US | disclosed |
| US-6730707-B2 | SUCH AS 5-(METHOXYCARBONYLAMINO)-N-ACETYLTRYPTAMINE; TREATING OCULAR HYPERTENSION, VARIOUS FORMS OF GLAUCOMA | INSPIRE PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| EP-1307191-A2 | USE OF INDOLE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR REDUCING INTRACULAR PRESSURE | Inspire Pharmaceuticals, Inc. (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2002-03-28 | — | — | US | disclosed |
| WO-2002009702-A2 | USE OF INDOLE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR REDUCING INTRACULAR PRESSURE | INSPIRE PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-0900080-A4 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 2000-12-13 | — | — | EP | disclosed |
| EP-0900080-A1 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997031636-A1 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198803-A1 | Such as 5-(methoxycarbonylamino)-N - acetyltryptamine; therapy for ocular hypertension; vision defects | MTNR1A, MTNR1B, MC5R | NISCH 1292/4885ADRA2A 292/4885ADRA2B 399/4885 |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | MTNR1A, MTNR1B, MC5R | NISCH 956/4885ADRA2A 315/4885ADRA2B 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.